Field Notes #4: Resilient Refiles, Definium's Readout, HRSA's RFI Responses, and J&J's Neuroplastogen Bet
Welcome to our fourth Field Note. As a reminder, Field Notes are timely, candid voice notes from our Founder and Editor, Josh Hardman, that give our Pα+ readers a pulse on recent developments in psychedelic drug development, policy, and access.
In this Field Note, Josh shares stories from another busy month in the field, including:
- Resilient Pharmaceuticals' refiling of its MDMA for PTSD new drug application
- Definium Therapeutics' first Phase 3 LSD for generalised anxiety disorder readout
- The U.S. Health Resources and Services Administration's receipt of 59 comments from stakeholders about the delivery of psychedelic therapies, if approved
- Johnson & Johnson's apparent involvement in Delix Therapeutics' Series C round
- Heidi Overton's nomination to FDA Commissioner
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In